This Article Full Text Full Text (PDF) All Versions of this Article: 91/12/4769    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Daly, A. F. Articles by Beckers, A. Search for Related Content PubMed PubMed Citation Articles by Daly, A. F. Articles by Beckers, A. Related Collections Neuroendocrinology and Pituitary Endocrine Oncology

High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, 4000 Liège, Belgium

Address all correspondence and requests for reprints to: Professor Albert Beckers, M.D., Ph.D., Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium. E-mail: albert.beckers{at}chu.ulg.ac.be.

Context: Prevalence data are important for assessing the burden of disease on the health care system; data on pituitary adenoma prevalence are very scarce.

Objective: The objective of the study was to measure the prevalence of clinically relevant pituitary adenomas in a well-defined population.

Design: This was a cross-sectional, intensive, case-finding study performed in three regions of the province of Liège, Belgium, to measure pituitary adenoma prevalence as of September 30, 2005.

Setting: The study was conducted in specialist and general medical practitioner patient populations, referral hospitals, and investigational centers.

Methods: Three demographically and geographically distinct districts of the province of Liège were delineated precisely using postal codes. Medical practitioners in these districts were recruited, and patients with pituitary adenomas under their care were identified. Diagnoses were confirmed after retrieval of clinical, hormonal, radiological, and pathological data; full demographic and therapeutic follow-up data were collected in all cases.

Results: Sixty-eight patients with clinically relevant pituitary adenomas were identified in a population of 71,972 individuals; the mean (± SD) prevalence was 94 ± 19.3 cases per 100,000 population (95% confidence interval, 72.2 to 115.8). The group was 67.6% female and had a mean age at diagnosis of 40.3 yr; 42.6% had macroadenomas and 55.9% underwent surgery. Prolactinomas comprised 66% of the group, with the rest having nonsecreting tumors (14.7%), somatotropinomas (13.2%), or Cushing’s disease (5.9%); 20.6% had hypopituitarism.

Conclusion: The prevalence of pituitary adenomas in the study population (one case in 1064 individuals) was more than 3.5–5 times that previously reported. This increased prevalence may have important implications when prioritizing funding for research and treatment of pituitary adenomas.

This article has been cited by other articles:

				P. Lancellotti, E. Livadariu, M. Markov, A. F Daly, M.-C. Burlacu, D. Betea, L. Pierard, and A. Beckers Cabergoline and the risk of valvular lesions in endocrine disease. Eur. J. Endocrinol., July 1, 2008; 159(1): 1 - 5. [Abstract] [Full Text] [PDF]

				R. Vazquez-Martinez, A. J. Martinez-Fuentes, M. R. Pulido, L. Jimenez-Reina, A. Quintero, A. Leal-Cerro, A. Soto, S. M. Webb, N. Sucunza, F. Bartumeus, et al. Rab18 Is Reduced in Pituitary Tumors Causing Acromegaly and Its Overexpression Reverts Growth Hormone Hypersecretion J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2269 - 2276. [Abstract] [Full Text] [PDF]

				J. Honegger, S. Zimmermann, T. Psaras, M. Petrick, M. Mittelbronn, U. Ernemann, M. Reincke, and K. Dietz Growth modelling of non-functioning pituitary adenomas in patients referred for surgery Eur. J. Endocrinol., March 1, 2008; 158(3): 287 - 294. [Abstract] [Full Text] [PDF]

				A. Beckers and A. F Daly The clinical, pathological, and genetic features of familial isolated pituitary adenomas Eur. J. Endocrinol., October 1, 2007; 157(4): 371 - 382. [Abstract] [Full Text] [PDF]

				L. A Naves, A. F Daly, J.-F. Vanbellinghen, L. A Casulari, C. Spilioti, A. V Magalhaes, M. F Azevedo, L. A Giacomini, P. P Nascimento, R. O Nunes, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene Eur. J. Endocrinol., October 1, 2007; 157(4): 383 - 391. [Abstract] [Full Text] [PDF]

				M Kars, A A van der Klaauw, C S Onstein, A M Pereira, and J A Romijn Quality of life is decreased in female patients treated for microprolactinoma Eur. J. Endocrinol., August 1, 2007; 157(2): 133 - 139. [Abstract] [Full Text] [PDF]

				P. Caturegli Autoimmune Hypophysitis: An Underestimated Disease in Search of Its Autoantigen(s) J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2038 - 2040. [Full Text] [PDF]

				A. F. Daly, J.-F. Vanbellinghen, S. K. Khoo, M.-L. Jaffrain-Rea, L. A. Naves, M. A. Guitelman, A. Murat, P. Emy, A.-P. Gimenez-Roqueplo, G. Tamburrano, et al. Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1891 - 1896. [Abstract] [Full Text] [PDF]

				K. Hemminki, A. Forsti, and J. Ji Incidence and familial risks in pituitary adenoma and associated tumors Endocr. Relat. Cancer, March 1, 2007; 14(1): 103 - 109. [Abstract] [Full Text] [PDF]